Industry
Biotechnology
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Loading...
Open
10.47
Mkt cap
1.3B
Volume
4M
High
11.35
P/E Ratio
-5.23
52-wk high
13.17
Low
10.35
Div yield
N/A
52-wk low
1.76
Portfolio Pulse from Benzinga Newsdesk
November 06, 2023 | 11:59 am
Portfolio Pulse from Benzinga Newsdesk
November 06, 2023 | 11:50 am
Portfolio Pulse from Benzinga Insights
November 03, 2023 | 1:05 pm
Portfolio Pulse from Lisa Levin
November 03, 2023 | 12:28 pm
Portfolio Pulse from Benzinga Newsdesk
November 03, 2023 | 11:32 am
Portfolio Pulse from Benzinga Insights
November 02, 2023 | 6:01 pm
Portfolio Pulse from Lisa Levin
October 27, 2023 | 10:43 am
Portfolio Pulse from Benzinga Newsdesk
October 26, 2023 | 6:43 pm
Portfolio Pulse from Lisa Levin
October 20, 2023 | 6:42 pm
Portfolio Pulse from Lisa Levin
October 20, 2023 | 5:45 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.